Invesco Ltd. Raises Holdings in Xencor, Inc. (NASDAQ:XNCR)

Invesco Ltd., a global investment management firm, has announced that it has raised its holdings in Xencor, Inc. (NASDAQXNCR), a biopharmaceutical company focused on developing and commercializing novel therapies for cancer and autoimmune diseases. The exact amount of the investment was not disclosed, but it is believed to be significant enough to increase Invesco's stake in Xencor.

Invesco has been investing in Xencor since 2018, when it first acquired a minority stake in the company. Since then, Invesco has continued to support Xencor's growth and development, providing strategic guidance and financial resources to help the company bring its innovative therapies to market.

Xencor is currently developing several promising therapies for cancer and autoimmune diseases, including a CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and an antibody-drug conjugate (ADC) for the treatment of multiple myeloma. These therapies are in various stages of development, with clinical trials ongoing to evaluate their safety and efficacy.

Invesco's investment in Xencor is a vote of confidence in the company's potential to deliver on its mission to transform patient lives through innovative therapies. With Invesco's support, Xencor is well-positioned to continue its growth and development, bringing new treatments to market for patients with cancer and autoimmune diseases.